Betta Pharmaceuticals Co.
300558 · SZSE ChiNext
Public Market Listing
Live quotes, historical charts, and market capitalization for Betta Pharmaceuticals Co. are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(9 total)
| Target & Modality | |||
|---|---|---|---|
Ensartinib(Ensacove) | Approved | ALKSmall molecule | Non-Small Cell Lung Cancer |
| Phase 3 | EGFRSmall molecule | Non-Small Cell Lung Cancer | |
| Phase 3 | EGFRSmall molecule | Non-Small Cell Lung Cancer | |
Tibremciclib(Kangmeina) | Phase 3 | CDK4 and CDK6Small molecule | Breast Cancer HR+/HER2- Metastatic Breast Cancer |
| Phase 2 | EGFR x c-METMultispecific antibody | Non-Small Cell Lung Cancer | |
| Phase 1/2 | EGFRSmall molecule | Non-Small Cell Lung Cancer | |
| Phase 1/2 | RAS (pan-RAS, RAS-mutant tumors)Small molecule | Non-Small Cell Lung Cancer | |
| Phase 1 | PD-L1Small molecule | Non-Small Cell Lung Cancer | |
| Phase 1 | EGFR L858R (including T790M/C797S resistant mutants)Small molecule | Non-Small Cell Lung Cancer |
Upcoming events
(6 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (5)
April 2028 (3)
November 2028 (1)
What to watch
December 2028 (1)
What to watch
2029 (1)
February 2029 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Annual history (1 year)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $497M | — | — | — | report ↗ |